Novel Targeted Anticancer Agents from Marine Cyanobacteria

来自海洋蓝藻的新型靶向抗癌剂

基本信息

批准号：
10005117
负责人：
HENDRIK LUESCH
金额：
$ 43.91万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-06 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10005117
关键词：
Antimetastatic Agent Antineoplastic Agents Bar Codes Biochemical Biological Biological Assay Breast Cancer Cell Cell Line Cells Characteristics Chemical Weapons Chemicals Collection Colorectal Cancer Coupled Cyanobacterium Cytotoxin Data Data Set Development Dolastatin 10 Drug resistance Event Florida Funding Future G-Protein-Coupled Receptors GSTP1 gene Gene Cluster Genes Genetic Growth HCT116 Cells Habitats Hawaii Histone Deacetylase Inhibitor Investigation Knowledge Laboratories Libraries Malignant Neoplasms Malignant neoplasm of pancreas Mass Spectrum Analysis Metagenomics Modeling Molecular Molecular Analysis Molecular Target Morphology Mus Natural Product Drug Natural Products Neoplasm Metastasis Nuclear Organism Pathway interactions Pattern Peptide Hydrolases Pharmaceutical Chemistry Phenotype Phylogenetic Analysis Planet Earth Reporter Genes Research Ribosomal RNA Sampling Source Structure Synthesis Chemistry Taxonomy Translating Validation Vascular Endothelial Growth Factors angiogenesis apratoxin base cancer cell cancer prevention cancer therapy carcinogenesis chemical synthesis colon cancer cell line cytotoxicity drug discovery efficacy study experience genetic information hypoxia inducible factor 1 in vivo inhibitor/antagonist innovation malignant breast neoplasm milligram novel novel anticancer drug novel therapeutics preservation programs prostate cancer cell rRNA Genes screening success tool transcription factor tumor xenograft

项目摘要

PROJECT SUMMARY Cyanobacteria are among the most ancient organisms on Earth and have evolved chemical weapons for defensive purposes, which we are exploiting for anticancer drug discovery. Our past research has exemplified that marine cyanobacteria produce compounds with exceptionally potent activity and/or possess unusual or first- in-class inhibitors with novel mechanisms of action. We apply a broad yet focused screening platform to maximize discovery rate of new anticancer agents. We also integrate a synthetic chemistry component into our program in order to perform rigorous biological studies to rapidly add value to our discoveries and to help solve the supply problem. Specifically, we will carry out field collections of marine cyanobacteria and prepare fraction libraries for screening in a set of innovative pathway-focused cell-based assays, utilizing various isogenic colorectal cancer cell lines and reporter gene assays, as well as newly developed unbiased phenotypic assays. We will perform dereplication, identify cyanobacteria through molecular analysis and establish phylogenetic relationships among benthic cyanobacteria. Samples will be prioritized based on bioactivity profiles and genetic uniqueness for further processing. Prioritized samples will be subjected to bioassay-guided isolation of the active compounds. Structures will be determined using NMR and mass spectrometry. Basic validation of bioactivity and secondary assays will be performed before prioritizing targets for further investigation. Selected compounds with intriguing structure and promising validated bioactivity will be targeted for total synthesis so that a rigorous biological characterization can be performed to pinpoint the molecular changes induced in the cancer cell and to determine potential direct targets. For novel noncytotoxic compounds that show potential antimetastatic activity, we will apply an orthogonal target-based screening platform.

项目摘要蓝细菌是地球上最古老的生物之一，已进化了化学武器防御目的，我们正在利用抗癌药物发现。我们过去的研究举例说明了海洋蓝细菌产生具有极有效活性的化合物和/或具有不寻常或首次的化合物具有新型作用机理的课堂抑制剂。我们将广泛但专注的筛选平台应用于最大化新抗癌剂的发现率。我们还将合成化学成分整合到我们的程序以进行严格的生物学研究以快速为我们的发现增加价值并帮助解决供应问题。具体而言，我们将进行海洋蓝细菌的现场收集并准备分数利用各种等源性结直肠癌细胞系和报告基因测定，以及新开发的无偏表型测定。我们将进行删除，通过分子分析鉴定蓝细菌并建立系统发育底栖蓝细菌之间的关系。样品将根据生物活性谱和遗传优先考虑进一步处理的独特性。优先样品将进行活性的生物测定指导隔离化合物。结构将使用NMR和质谱法确定。生物活性的基本验证在优先级目标之前，将进行次要测定，以进行进一步研究。选定的化合物通过有趣的结构和有希望的经过验证的生物活性，将成为全合成的目标，以便严格可以进行生物学表征以查明癌细胞中诱导的分子变化和确定潜在的直接目标。对于显示出潜在的抗转移活性的新型非毒性化合物，我们将应用一个基于目标的筛选平台。